Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We investigated the clinical impact of genomic and pathway alterations in stage I epidermal growth factor receptor (EGFR)–mutant lung adenocarcinomas, which have a high recurrence rate despite complete surgical resection. Materials and Methods Out of the initial cohort of 257 patients with completely resected stage I EGFR-mutant lung adenocarcinoma, tumor samples from 105 patients were subjected to analysis using large-panel next-generation sequencing. We analyzed 11 canonical oncogenic pathways and determined the number of pathway alterations (NPA). Survival analyses were performed based on co-occurring alterations and NPA in three patient groups: all patients, patients with International Association for the Study of Lung Cancer (IASLC) pathology grade 2, and patients with recurrent tumors treated with EGFR–tyrosine kinase inhibitor (TKI). Results In the univariate analysis, pathological stage, IASLC grade, TP53 mutation, NPA, phosphoinositide 3-kinase pathway, p53 pathway, and cell cycle pathway exhibited significant associations with worse recurrence-free survival (RFS). Moreover, RPS6KB1 or EGFR amplifications were linked to a poorer RFS. Multivariate analysis revealed that pathologic stage, IASLC grade, and cell cycle pathway alteration were independent poor prognostic factors for RFS (p=0.002, p < 0.001, and p=0.006, respectively). In the grade 2 subgroup, higher NPA was independently associated with worse RFS (p=0.003). Additionally, in patients with recurrence treated with EGFR-TKIs, co-occurring TP53 mutations were linked to shorter progression-free survival (p=0.025). Conclusion Genomic and pathway alterations, particularly cell cycle alterations, high NPA, and TP53 mutations, were associated with worse clinical outcomes in stage I EGFR-mutant lung adenocarcinoma. These findings may have implications for risk stratification and the development of new therapeutic strategies in early-stage EGFR-mutant lung cancer patients.
Abstract
Purpose We investigated the clinical impact of genomic and pathway alterations in stage I epidermal growth factor receptor (EGFR)–mutant lung adenocarcinomas, which have a high recurrence rate despite complete surgical resection. Materials and Methods Out of the initial cohort of 257 patients with completely resected stage I EGFR-mutant lung adenocarcinoma, tumor samples from 105 patients were subjected to analysis using large-panel next-generation sequencing. We analyzed 11 canonical oncogenic pathways and determined the number of pathway alterations (NPA). Survival analyses were performed based on co-occurring alterations and NPA in three patient groups: all patients, patients with International Association for the Study of Lung Cancer (IASLC) pathology grade 2, and patients with recurrent tumors treated with EGFR–tyrosine kinase inhibitor (TKI). Results In the univariate analysis, pathological stage, IASLC grade, TP53 mutation, NPA, phosphoinositide 3-kinase pathway, p53 pathway, and cell cycle pathway exhibited significant associations with worse recurrence-free survival (RFS). Moreover, RPS6KB1 or EGFR amplifications were linked to a poorer RFS. Multivariate analysis revealed that pathologic stage, IASLC grade, and cell cycle pathway alteration were independent poor prognostic factors for RFS (p=0.002, p < 0.001, and p=0.006, respectively). In the grade 2 subgroup, higher NPA was independently associated with worse RFS (p=0.003). Additionally, in patients with recurrence treated with EGFR-TKIs, co-occurring TP53 mutations were linked to shorter progression-free survival (p=0.025). Conclusion Genomic and pathway alterations, particularly cell cycle alterations, high NPA, and TP53 mutations, were associated with worse clinical outcomes in stage I EGFR-mutant lung adenocarcinoma. These findings may have implications for risk stratification and the development of new therapeutic strategies in early-stage EGFR-mutant lung cancer patients.
참고문헌 (32)
- Chansky K, "The IASLC Lung Cancer Staging Project : external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer", J Thorac Oncol, 12, pp.1109~1121 (2017)
- Jeon DS, "Five-year overall survival and prognostic factors in patients with lung cancer : results from the Korean Asso ciation of Lung Cancer Registry(KALC-R)2015", Cancer Res Treat, 55, pp.103~111 (2023)
- Wu YL, "Osi mertinib in resected EGFR-mutated non-small-cell lung can cer", N Engl J Med, 383, pp.1711~1723 (2020)
- Liu SY, "Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes", Nat Commun, 12, pp.6450~ (2021)
- Christopoulos P, "Risk stratification of EGFR(+)lung can cer diagnosed with panel-based next-generation sequencing", Lung Cancer, 148, pp.105~112 (2020)
- Shukla S, "Development of a RNA-Seq based prognostic signa ture in lung adenocarcinoma", J Natl Cancer Inst, 109, pp.djw200~ (2017)
- Patnaik SK, "Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection", Cancer Res, 70, pp.36~45 (2010)
- Soltis AR, "Proteogenomic analysis of lung adenocarcinoma reveals tumor heterogeneity, survival determinants, and therapeuti cally relevant pathways", Cell Rep Med, 3, pp.100819~ (2022)
- Park E, "Detection of targetable genetic alterations in Korean lung cancer patients : a comparison study of single gene assays and targeted next-generation sequencing", Cancer Res Treat, 52, pp.543~551 (2020)
- Moreira AL, "A grading system for invasive pulmonary sde nocarcinoma : a proposal from the International Association for the Study of Lung Cancer Pathology Committee", J Thorac Oncol, 15, pp.1599~1610 (2020)
- Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer : a joint consen sus recommendation of the Association for Molecular Pathol ogy, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
- Sanchez-Vega F, "Oncogenic signaling pathways in The Cancer Genome Atlas", Cell, 173, pp.321~337 (2018)
- Zhou J, "Analysis of tumor genomic pathway alterations using broad-panel next-generation sequencing in surgically resect ed lung adenocarcinoma", Clin Cancer Res, 25, pp.7475~7484 (2019)
- Kadota K, "Cribriform subtype is an independent predictor of recurrence and survival after adjustment for the eighth edi tion of TNM staging system in patients with resected lung adenocarcinoma", J Thorac Oncol, 14, pp.245~254 (2019)
- Ujiie H, "Solid predominant histologic subtype in resected stage I lung adenocarcinoma is an independent predictor of early, extrathoracic, multisite recurrence and of poor postrecur rence survival", J Clin Oncol, 33, pp.2877~2884 (2015)
- Nitadori J, "Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarci noma of 2cm or smaller", J Natl Cancer Inst, 105, pp.1212~1220 (2013)
- Deng C, "Valida tion of the novel International Association for the Study of Lung Cancer grading system for invasive pulmonary adeno carcinoma and association with common driver mutations", J Thorac Oncol, 16, pp.1684~1693 (2021)
- Rokutan-Kurata M, "Validation study of the International Association for the Study of Lung Cancer histologic grading system of invasive lung adenocarcinoma", J Thorac Oncol, 16, pp.1753~1758 (2021)
- Park BJ, "Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma : the importance of the lepidic proportion", Lung Cancer, 175, pp.1~8 (2023)
- Skoulidis F, "Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy", Nat Rev Cancer, 19, pp.495~509 (2019)
- Caso R, "The underlying tumor genomics of predomi nant histologic subtypes in lung adenocarcinoma", J Thorac Oncol, 15, pp.1844~1856 (2020)
- Canale M, "Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhi bitors", Clin Cancer Res, 23, pp.2195~2202 (2017)
- Kim IA, "Targeted next-generation sequencing analysis predicts the recurrence in resected lung adenocarcinoma harboring EGFR mutations", Cancers(Basel), 13, pp.3632~ (2021)
- Jung HA, "Clinical, pathologic, and molecular prognostic factors in patients with early-stage EGFR-mutant NSCLC", Clin Cancer Res, 28, pp.4312~4321 (2022)
- Nahar R, "Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequenc ing", Nat Commun, 9, pp.216~ (2018)
- Vokes NI, "Concurrent TP53 mutations facilitate resistance evolu tion in EGFR-mutant lung adenocarcinoma", J Thorac Oncol, 17, pp.779~792 (2022)
- Perez-Tenorio G, "Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer", Breast Cancer Res Treat, 128, pp.713~723 (2011)
- Chen B, "Hyperphosphorylation of RPS6KB1, rather than overexpres sion, predicts worse prognosis in non-small cell lung cancer pati-ents", PLoS One, 12, pp.e0182891~ (2017)
- Kim M, "Prognostic factors of acinar-or papillary-predominant adenocarcinoma of the lung", Lung Cancer, 137, pp.129~135 (2019)
- Chaft JE, "Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer", Nat Rev Clin Oncol, 18, pp.54757~ (2021)
- Lengel HB, "The emerging importance of tumor genomics in operable non-small cell lung cancer", Cancers(Basel), 13, pp.3656~ (2021)
- Ahn B, "Clin icopathologic and genomic features of high-grade pattern and their subclasses in lung adenocarcinoma", Lung Cancer, 170, pp.176~184 (2022)